Expression of IR21a, IR93a, and IR25a proteins decreases in DOCCs at the late third instar. by Jordan J. Tyrrell (10535989)

“…Right: <i>Ir21a>GFP-</i>labeled DOCCs express IR21a (Fig 4A), IR93a (Fig 4C) and IR25a (Fig 4E) proteins at 72 hr AEL (top), which are significantly decreased at 120 hr AEL (bottom). …”

Knockdown of MRPL28 results in a dose-dependent decrease in mitochondrial function. by Yijun Chen (107514)

Rodents engineered with CHIP-T246M had decreased expression of CHIP in the brain and testes, Purkinje cell degeneration, increased mortality, and selective tissue atrophy. by Chang-he Shi (5315918)

MiR-16 decreases protein expression of VPS4a. by Neeta Adhikari (474583)

“…<p>VPS4a protein is decreased following overexpression of miR-16. …”

Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

CD14^dimCD16+ cells were at decreased frequency in fresh PBMCs of both BeS-NS and CBD. by Li Li (14993)

TGF-β1 had little effect on MMP-2, MMP-3 and MMP-14 expression, but decreased expression of MMP-16. by Youssef M. Farhat (295089)

Cre-mediated activation of RIαB allele specifically in the liver decreases PKA activity in vivo. by Brandon S. Willis (353418)

MxB decreases the nuclear γH2AX foci induced by L1 retrotransposition. by Yu Huang (15093)

SRPO significantly decreased leukocyte-endothelial interactions and serum MCP-1 level. by Hiroshi Kataoka (270804)

3D interactions between the ligand and the protein_DNA complex in the first (C1) and second (C2) clusters. by Ahmed A. Gaber (13302308)

Subjects:

Binding of amsacrine with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

The center of mass distances between the protein-DNA complex and the ligand (Blue line), and the protein and DNA (red line). by Ahmed A. Gaber (13302308)

Subjects:

Fig 12 - by Ahmed A. Gaber (13302308)

Subjects:

The number of clusters, number of interactions, and their types between the ligand and protein_DNA complex. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 17 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects:

Fig 4 - by Ahmed A. Gaber (13302308)

Subjects:

Some reported DNA intercalators and their basic pharmacophoric features. by Ahmed A. Gaber (13302308)

Subjects:

The contributions from the different energy components of MM-GBSA. by Ahmed A. Gaber (13302308)

Subjects:

Binding of compound 19 with DNA-Topo II complex. by Ahmed A. Gaber (13302308)

Subjects: